Home » Stocks » 9 Meters Biopharma

9 Meters Biopharma, Inc. (NMTR)

Stock Price: $0.570 USD 0.095 (20.00%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $0.580 +0.010 (1.75%) Aug 14, 7:58 PM

Stock Price Chart

Key Info

Market Cap 79.19M
Revenue (ttm) n/a
Net Income (ttm) -66.33M
Shares Out 136.23M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $0.570
Previous Close $0.475
Change ($) 0.095
Change (%) 20.00%
Day's Open 0.478
Day's Range 0.470 - 0.578
Day's Volume 6,309,920
52-Week Range 0.370 - 1.290

More Stats

Market Cap 79.19M
Enterprise Value 70.13M
Earnings Date (est) Mar 25, 2021
Ex-Dividend Date n/a
Shares Outstanding 136.23M
Float 67.92M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -0.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.55M
Short Ratio 0.80
Short % of Float 2.05%
Beta -0.67
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.70
Revenue n/a
Operating Income -56.49M
Net Income -66.33M
Free Cash Flow -16.05M
Net Cash 9.06M
Net Cash / Share 0.07
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -193.21%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.00*
Low
5.00
Current: $0.570
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue---4.078.2711.34
Revenue Growth----50.82%-27.13%-
Gross Profit---0.740.430.23
Operating Income-24.28-18.22-11.17-5.94-6.46-6.68
Net Income-27.05-24.16-11.61-6.21-8.74-11.06
Shares Outstanding33.3324.7611.890.550.330.28
Earnings Per Share-0.81-0.98-0.98-11.26-26.50-39.50
Operating Cash Flow-17.97-15.17-5.10-8.43-1.73-7.45
Capital Expenditures-0.01-0.01-0.04---
Free Cash Flow-17.98-15.18-5.14-8.43-1.73-7.45
Cash & Equivalents4.675.800.361.450.120.10
Total Debt3.185.208.570.043.725.09
Net Cash / Debt1.480.61-8.221.42-3.60-4.99
Assets5.306.450.806.464.726.41
Liabilities14.9110.1112.973.9810.4111.40
Book Value-9.61-3.66-12.172.49-5.69-4.99
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name 9 Meters Biopharma, Inc.
Country United States
Employees 8
CEO John Temperato

Stock Information

Ticker Symbol NMTR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NMTR

Description

9 Meters Biopharma, Inc., a gastrointestinal platform company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 analogue for SBS; Larazotide, a Phase 3-stage therapeutic in development for celiac disease; and NM-003, a long-acting GLP-2 analogue, which is under orphan indication selection. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.